Edition:
United States

Galapagos NV (GLPG.OQ)

GLPG.OQ on NASDAQ Stock Exchange Global Select Market

106.26USD
3:59pm EST
Change (% chg)

$1.91 (+1.83%)
Prev Close
$104.35
Open
$104.87
Day's High
$106.26
Day's Low
$104.87
Volume
20,295
Avg. Vol
49,723
52-wk High
$122.28
52-wk Low
$85.00

Chart for

About

No overview information found for .

Overall

No Ratios Available.

Financials

  GLPG.OQ Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -- -- --
ROI: -- 8.99 14.48
ROE: -- 10.13 15.99

BRIEF-Galapagos And Fibrocor Sign Partnership Focusing On Fibrosis

* SAID ON FRIDAY FIBROCOR THERAPEUTICS L.P. AND GALAPAGOS SIGN PARTNERSHIP FOCUSING ON FIBROSIS

Jan 07 2019

Rheinmetall says in talks to buy stake in rival Krauss-Maffei

FRANKFURT Rheinmetall on Monday said it was in talks about buying a stake in rival KMW and Nexter Defense Systems N.V, sending shares in the defense company sharply higher.

Nov 26 2018

Rheinmetall says in talks to buy stake in rival Krauss-Maffei

FRANKFURT, Nov 26 Rheinmetall on Monday said it was in talks about buying a stake in rival KMW and Nexter Defense Systems N.V, sending shares in the defense company sharply higher.

Nov 26 2018

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON FRIDAY A SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES

Nov 26 2018

BRIEF-Galapagos Reports Top-line Interim Results Of FALCON Trial Part 1 In CF

* REPORTED ON WEDNESDAY TOPLINE INTERIM RESULTS OF FALCON TRIAL PART 1 IN CF

Oct 25 2018

BRIEF-Galapagos 9-Month Revenue Rises To 205.1 Million Euros

* REPORTED ON WEDNESDAY 9-MONTH GROUP REVENUES INCREASED BY EUR 98.7 MILLION TO EUR 205.1 MILLION

Oct 25 2018

BRIEF-Galapagos Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis

* REPORTED TOGETHER WITH GILEAD SCIENCES ON SUNDAY PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS

Oct 22 2018

BRIEF-Galapagos: Capital Increase Of EUR 2.0 Million

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES

Oct 04 2018

UPDATE 1-Galapagos, Gilead bask in $4-6 bln new drug sales hope

LONDON, Sept 12 Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

Sep 12 2018

Galapagos shares soar on $4-6 billion hopes for new drug

LONDON Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

Sep 12 2018

Earnings vs. Estimates